The T2 Study is fully enrolled! Many thanks to the participants, study partners, friends, and family in helping advance Alzheimer’s disease clinical research.

Watch below to learn more about the T2 Protect AD Study
Troriluzole Trial for Alzheimer's Disease
(T2 Protect AD)

T2 Protect AD is a clinical trial testing the investigational drug troriluzole in people with mild to moderate Alzheimer’s disease (AD). T2 Protect AD is taking place at dozens of sites across the United States.

The study is designed to determine if troriluzole can protect against, slow down, and potentially improve memory and thinking problems that increase as Alzheimer’s disease progresses.

More About T2 Protect AD

A potential participant goes through a screening process to determine if he/she is eligible for the T2 Protect clinical trial. Screening includes memory and thinking tests, physical examination, and EKG (heart rhythms).

Participation in the study takes 48 weeks. Study participants visit the study clinic 9 times after enrollment in the trial. At the beginning and end of the study, participants have a brain scan using magnetic resonance imaging (MRI).

Half of study participants are given the active drug and half are given an inactive pill (called a placebo) that looks exactly like the active drug.

T2 Protect AD Basic Eligibility Criteria
  • Women and men aged 50-85 with mild to moderate Alzheimer’s disease (otherwise, in general good health)

  • On stable doses of donepezil (Aricept®) or rivastigmine (Exelon®) or galantamine (Razadyne®) for at least 3 months with or without memantine (Namenda®)

  • Living in the community (not in a residential nursing home)

  • Having a study partner who has regular contact with the trial participant (about 10 hours per week). The study partner will accompany the participant to the clinic visits

  • Willing to participate in the T2 Study for 48 weeks

Study-related health monitoring

Memory and thinking tests

MRI scans (a picture of your brain that shows changes related to Alzheimer's disease)

EKGs (a look at your heart rhythms)

Blood and urine tests


T2 Protect AD is taking place at more than 30 academic medical centers and clinics specialized in Alzheimer’s disease research, treatment, and care across the United States.

Enter your ZIP code, use the interactive map, or search the listings below to find a location near you.

      T2 in the News
      Clinical trial in NEPA for possible Alzheimer’s treatment
      Dr. Sharon Brangman, SUNY Upstate, talks about T2
      SIU Med School helps test promising new Alzheimer's treatment
      The Register Guard: From bugs to brainsStamford institute seeks candidates for Alzheimer’s clinical trial
      T2 Protect Study Starts in PhoenixTulsa Clinical Research Ready for T2 Participants in Oklahoma
      Neuroscientists discuss T2 on Alzheimer’s Speaks RadioPennington researcher: Louisiana can help in fight against Alzheimer's
      Northwestern Adds T2 to Its Strong Clinical Study LineupIn South Carolina, T2 part of innovative program at Roper St. Francis
      U of Miami Neurologist Talks About T2Roper St. Francis in South Carolina, Dr. Mintzer and the T2 Study ABC 4 News in Charleston
      Jersey Matters Interview with Dr. Irfan Qureshi Discussing T2 StudyNew Nationwide Alzheimer’s Study Coordinated by UCSD
      Forbes Features T2KPBS New Alzheimer’s Drug Could Slow Or Halt Disease Progression
      Clinical trial for Alzheimer’s drug happening at UC San DiegoCan This Novel Treatment Slow Alzheimer’s? Volunteers in NJ Are Needed to Help Find Out
      New Drug Trial Takes Different Approach to Stop Alzheimer'sNew drug could help with Alzheimer’s
      OSU looking for participants in Alzheimer's studyNew Alzheimer's drug tested at Vanderbilt seeks to slow or stop memory loss
      New Drug Trial Could Halt Alzheimer’s Memory LossMichigan universities testing new Alzheimer's drug
      New Haven Drugmaker Starting Clinical Trial Of Alzheimer's TreatmentCheck out our study in this article: New Alzheimer’s drug undergoing trials at two Connecticut sites

      In addition to T2, the Alzheimer’s Disease Cooperative Study (ADCS) at the University of California, San Diego has several studies underway across the U.S. Please visit